Soluble CD23 Expression in Asthma Patients Treated With OMA

Stopped early · Not applicable

Conditions studied: Asthma

In brief

This study involves a FDA approved drug, Omalizumab, used in the treatment of moderate to severe allergic asthma that cannot be controlled by standard treatment. It works on IgE to control the allergic reaction. We are looking at the effects on non-allergic asthma. We hope to prove that Omalizumab will have the same effect on non-allergic asthmatics as it does allergic asthmatics.

Key facts

Study ID

NCT00226200

Run by

University of Mississippi Medical Center

People needed

80

Starts

2004-11-01

Expected to finish

2007-10-01

Last updated by the study team

2008-12-01

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe asthmatic (based on 1997 NHLBI guidelines), controlled by medication for at least 6 months, initial IgE level between 30 and 700 IU, weigh between 30 an 150 kg, otherwise healthy.

You may not qualify if…

• Smoker, uncontrolled asthma, immunotherapy in past six weeks, other diseases

Where it is running

• University of Mississippi Medical Center — Jackson, Mississippi, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.